Reduced infusion time with VYXEOS
Dosing and administration schedules for VYXEOS and 7+3a in the Phase 3 trial1,2
Second Induction (if needed)
- Cytarabine and daunorubicin.
References: 1. VYXEOS [package insert]. Palo Alto, CA: Jazz Pharmaceuticals. 2. Data on file. VYX-2017-008. Palo Alto, CA: Jazz Pharmaceuticals. 3. Kolitz JE, Strickland SA, Cortes JE, et al. Efficacy by consolidation administration site: subgroup analysis of a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2‑6, 2017; Chicago, IL.
VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.Important Safety Information